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Ketogenic diet effects 
on inflammatory allodynia 
and ongoing pain in rodents
David N. Ruskin*, Isabella C. Sturdevant, Livia S. Wyss & Susan A. Masino
Ketogenic diets are very low carbohydrate, high fat, moderate protein diets used to treat medication-
resistant epilepsy. Growing evidence suggests that one of the ketogenic diet’s main mechanisms of 
action is reducing inflammation. Here, we examined the diet’s effects on experimental inflammatory 
pain in rodent models. Young adult rats and mice were placed on the ketogenic diet or maintained 
on control diet. After 3–4 weeks on their respective diets, complete Freund’s adjuvant (CFA) was 
injected in one hindpaw to induce inflammation; the contralateral paw was used as the control. 
Tactile sensitivity (von Frey) and indicators of spontaneous pain were quantified before and after 
CFA injection. Ketogenic diet treatment significantly reduced tactile allodynia in both rats and mice, 
though with a species-specific time course. There was a strong trend to reduced spontaneous pain in 
rats but not mice. These data suggest that ketogenic diets or other ketogenic treatments might be 
useful treatments for conditions involving inflammatory pain.
Acute inflammation is a process in which the innate immune system reacts to tissue infection, irritation, or dam-
age to destroy the infecting pathogen, remove the irritating agent and begin repair of tissue damage. As such, 
it is a normal and beneficial process. If inflammation is not resolved, however, it will become a chronic state in 
which healthy tissue is harmed. Chronic inflammation is intertwined inexorably with chronic oxidative stress 
and elevated levels of free radicals and reactive oxygen  species1. Oxidative stress is a key player in many chronic 
inflammation-related dysfunctions  peripherally2–5 and  centrally6–9. Notably, pain is a major symptom in many 
inflammation-related disorders, including diabetic neuropathy, chemotherapeutic neuropathy, gout, rheumatoid 
arthritis, inflammatory bowel disease, and fibromyalgia. Often the pain takes the form of allodynia, a state in 
which innocuous stimuli are perceived as painful.
Prior studies have shown that diet can influence inflammatory pain, e.g.10–12. There is growing evidence that 
the ketogenic diet (KD) is anti-inflammatory. This diet was introduced as an anticonvulsant treatment for drug-
refractory epilepsy, and has very low carbohydrate content as a means to induce a metabolic state similar to fast-
ing but without caloric restriction. In this metabolic state, the liver converts fatty acids to ketone bodies which 
circulate to be used by other tissues as fuel during reduced availability of glucose; a ketone body-based metabo-
lism should produce fewer free radicals than one based on  glucose13. The KD should reduce inflammation as it 
enhances various antioxidant  mechanisms14–26. Indeed, KD treatment reduces reactive oxygen  species17,18,27–32, 
limits oxidative damage to  DNA17,20,33,  lipids29,34–37, and  proteins16,20,23,35, and modulates immune cell  function28,38. 
Most of these studies did not use a calorie-restricted KD. In spite of the conceptual overlap among inflammation, 
pain, oxidative stress, and the KD, there has been very little work on the KD as a treatment for inflammatory pain. 
Here we tested a KD in a rodent model of experimental inflammatory pain, specifically investigating allodynia 
and measures of spontaneous pain.
Methods
All procedures were performed in accordance with the NIH Guide for the Care and Use of Laboratory Ani-
mals, and approved by the Institutional Animal Care and Use Committee of Trinity College (A3869-01). Male 
Sprague–Dawley rats and male C57Bl/6 mice were bred in-house (original stock from Charles River), and pair-
housed (rats) or group-housed (mice) in 12 h:12 h light:dark conditions. Treatment started at 10–16 week of 
age (rats) or 6–8 week (mice). Animals remained on their control diet (CD; LabDiet 5001) or were switched to 
a KD (BioServ 3666); all diets were provided ad libitum. KD was replaced daily. Diet treatment proceeded for 
three or four weeks before behavioral studies began, and continued through the end of experimentation. Animals 
were gently handled daily for several days before testing, to reduce handling stress during behavioral studies 
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and to make animals docile for paw volume testing. All testing occurred during the lights-on period of the daily 
cycle. For rats, 100 µl complete Freund’s adjuvant (CFA; Thermo Scientific, 0.5 mg/ml) was injected intraplantar 
into the right hindpaw with the needle tip as close to the center of the footpads as possible; for mice, injections 
were similar apart from reducing the dose of CFA to 20 μl. All CFA injections were performed in the morning 
to keep the four h time point well within the light cycle. Volumes of rat right hindpaws before CFA injection 
did not differ between CD- and KD-fed groups (p > 0.50), such that the 100 µl dose of CFA can be considered 
equivalent in the two groups.
Before tactile sensitivity testing, rats were habituated by being brought in their home cage into the testing 
room for 15 min, then placed on an elevated mesh stand in 20 × 20 × 12 cm acrylic enclosures (to minimize loco-
motion; IITC) for another 15 min; mice were habituated by being placed on the mesh stand in 10 × 10 × 12 cm 
acrylic enclosures (IITC) for 60 min. At various times before and after CFA injection, tactile sensitivity was 
measured with an electronic von Frey probe (IITC, Fig. 1). The rigid von Frey probe was applied alternately to 
each hindpaw until the animal either withdrew the paw or allowed it to be lifted by the probe; the maximum 
force on each trial was recorded. Three trials with no less than a 120 s intertrial interval occurred per hindpaw. 
If the animal began to take a step or otherwise shift its position during a trial, that trial was repeated. 
In rats, spontaneous pain behavior was assessed 48 h prior to and 24 h after CFA injection. After a 15 min 
habituation to the testing room, animals were placed singly in 19 × 29 × 13 cm clear-bottom cages for 30 min 
and filmed vertically from below. Later, videos were watched for indications of spontaneous pain for 60 s every 
five minutes; videos were watched by two scorers who were independent and blind to dietary treatment and 
pre- versus post-CFA state. Epochs with grooming or locomotion were avoided. Position of each hindpaw was 
placed into the following categories: 0, normal weight bearing; 1, light weight bearing; 2, only paw edge touching 
floor; 3, paw nearly raised off floor; 4, paw completely raised; 5, licking raised paw, and time spent in each posi-
tion was recorded. For each observed minute, a weighted pain score was calculated  (t1 + 2t2 + …  5t5, in which  tx 
is the time spent in category x) and averaged across the six observed  minutes39. This test was not used in mice 
as preliminary experiments indicated that mouse paws were too small to reliably distinguish the categories.
In rodents, ongoing painful states interfere with ongoing  behavior40–42. We assessed this effect in mice with 
marble  burying43–45 at the indicated times (Fig. 1). Animals were habituated to the testing room for 30 min, then 
placed individually in 19 × 29 × 13 cm cages for 30 min. These cages had a 3 × 5 array of 1.6 cm diameter black 
marbles placed on five cm of wood ship bedding. Photos were taken vertically from above before and after the 
session and analyzed with Photoshop. The quick selection tool was used to measure the total number of pixels 
associated with the black marbles, and the polygonal lasso tool was used to measure the number of pixels of 
the bedding field; the number of marble pixels was expressed as a percentage of the entire field’s pixels. This 
calculation was performed on before and after pictures, with the comparative decrease in the marble percentage 
compared to before indicating the amount of burying. Data from two mice that demonstrated very little bury-
ing in the baseline test were excluded from analysis. The marble burying test was not used in rats as preliminary 
experiments indicated that rats did virtually no burying under our conditions.
Volumes of rat hindpaws were measured by water volume displacement in 25 ml graduated cylinders 24 h 
prior to and 50 h after CFA injection. At sacrifice of subjects, glucose and the ketone body β-hydroxybutyrate 
were measured in tail vein blood with Precision Xtra meters (Abbott).
Figure 1.  Timeline of experimental procedures in rats and mice.
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T-tests were used for CD versus KD comparisons, with significance indicated by pound signs. For com-
parisons of post-CFA time points to baseline time points, multiple Bonferroni comparisons were made, with 
significance indicated by asterisks. Comparisons were considered significant if p < 0.05. All data are presented 
as mean ± standard error.
Results
Plantar tactile sensitivity was low in baseline and not different between CD- and KD-fed rats in injected paws 
(CD 85.0 ± 7.0 g, KD 85.4 ± 10.6 g, p > 0.50) or uninjected paws (CD 95.6 ± 7.3 g, KD 80.8 ± 9.2 g, g > 0.20). All rats 
demonstrated strong allodynia of the injected hindpaw; however the magnitude of this effect was significantly 
smaller at 4 h post-injection in KD-fed animals (Fig. 2). This difference did not remain significant at the 48 h 
time point (Fig. 2). As expected, plantar tactile sensitivity did not change with diet or time in the uninjected 
hindpaw (Fig. 2). 
Behaviors indicative of ongoing pain states related to the hindpaws such as licking and avoiding weight 
bearing were essentially absent pre-CFA, as expected (Fig. 3). After injection, such behaviors were present and 
directed to only the injected hindpaw in all rats; however there was a strong trend toward less such behavior in 
KD-fed rats (Fig. 3). 
As  expected46, CFA-induced hindpaw swelling was significantly reduced by KD treatment, measured by 
change in volume from baseline (Fig. 4). The uninjected hindpaw was unaffected (Fig. 4).
Plantar tactile sensitivity was low in baseline and not different between CD- and KD-fed mice in injected paws 
(CD 3.18 ± 0.63 g, KD 2.72 ± 0.47 g, p > 0.50) or uninjected paws (CD 2.84 ± 0.15 g, KD 2.46 ± 0.32 g, g > 0.30).). 
All mice demonstrated robust tactile allodynia of the CFA-injected hindpaw; however, in CD-fed mice signifi-
cant allodynia remained out to the last time point assessed (7d), whereas in KD-fed mice allodynia was starting 
to reverse at 2d and tactile sensitivity was no longer different from baseline at 4d (Fig. 5). As expected, plantar 
tactile sensitivity did not change with diet or time in the uninjected hindpaw (Fig. 5).
Figure 2.  Effects of CFA and diet treatment on tactile allodynia in rats assessed by electronic von Frey probe. 
For the injected paw, all 4 h and 48 h groups are significantly different from baseline (not indicated). There were 
no treatment effects on control paw sensitivity. Control n = 14, ketogenic n = 12. #p < 0.05 control v. ketogenic 
diet.
Figure 3.  Effects of CFA and diet treatment on spontaneous expression of pain in rats. The spontaneous pain 
score was calculated from observations on paw favoring, lifting, and licking before and 24 h after CFA injection. 
For the injected paw, spontaneous pain was significantly higher compared to pre-injection for both groups (not 
indicated). However, there was a strong trend for spontaneous pain to be lower in ketogenic diet-treated rats. 
There were no effects regarding the uninjected paw. Control n = 14, ketogenic n = 12. #p = 0.059.
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Baseline marble burying was not different between CD- and KD-fed mice (CD 45.2 ± 9.5% buried, KD 
32.3 ± 4.7% buried, p > 0.20). Marble burying in mice was strikingly reduced after CFA injection, likely indicat-
ing an ongoing pain state (Fig. 6). Burying behavior slowly recovered in both diet groups; and statistics indicated 
that there was no diet-related difference in recovery rate. Notably, at 4 and 7 days the KD group is burying at 
levels above baseline, albeit non-significantly, something not found in the CD group (Fig. 6). 
Figure 4.  Effects of dietary treatment on CFA-induced inflammatory paw swelling in rats. Paw volume was 
expressed as the difference between volume at 50 h after CFA injection and volume at baseline. There was 
significantly less swelling in rats fed the ketogenic diet. There was no effect in control paws. Control n = 14, 
ketogenic n = 10. #p < 0.05.
Figure 5.  Effects of CFA and diet treatment on tactile allodynia in mouse assessed by electronic von Frey probe. 
Injected paws became hypersensitive after CFA injection, but the rate of recovery differed in the groups. Control 
diet-fed mice were still strongly hypersensitive at the last examined timepoint, whereas a gradual and complete 
recovery occurred in ketogenic diet-fed mice. There were no effects in the uninjected paw. Control n = 6, 
ketogenic n = 8. ***p < 0.001, **p < 0.05, (*)p = 0.071 compared to baseline.
Figure 6.  Effects of ongoing pain and dietary treatment on marble burying in mice. CFA injection reduced 
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Ketogenic diet treatment strongly elevated blood ketone bodies in both species, reduced blood glucose in 
mice, and produced a trend for decreased mouse body mass (Table 1).
Discussion
We found that treatment with a KD significantly ameliorated CFA-induced tactile allodynia in two model 
species, with more modest effects on indices of ongoing spontaneous pain. A KD-induced amelioration of 
induced inflammatory pain in rodents is consonant with the KD’s reduction of inflammation itself produced 
by various insults in various tissues in  rodents19,28,31,46–53 and  patients54–56, and reducing pro-inflammatory 
 cytokines19,28,37,47,49,57–60 and  eicosanoids55,58 while elevating anti-inflammatory  cytokines60,61. These results may 
appear to contradict a large body of literature showing that high-fat diets promote  inflammation62. However, 
this literature refers to diets such as the Western or standard American diet (SAD), high in fat but not low in 
carbohydrates. The metabolic response to dietary fats differs greatly depending on the presence of carbohydrates: 
the high‐fat‐plus‐carbohydrate diet promotes fat storage, whereas the high fat, low‐carbohydrate diet promotes 
fat  metabolism63. Recently, KD feeding was shown to reverse the tactile allodynia produced in a mouse model 
of metabolic  syndrome64 (strikingly, the KD in this study had almost twice the fat level of the high-fat/moderate 
carbohydrate diet that induced metabolic syndrome). Metabolic syndrome-related allodynia relates to inflam-
mation in the peripheral nervous  system65, and as diabetic neuropathy is thought also to involve inflammation in 
the spinal  cord66, beneficial effects of the KD against pain syndromes involving inflammation could be peripheral, 
central, or both. KD treatment, however, appears not to be equally effective in all neuropathic pain  syndromes67 
possibly relating to involvement of inflammation.
Clinical work with KD and pain had a very early start, specifically regarding  migraine68,69 and this use may 
be undergoing a  resurgence70. Notably, oxidative stress has been hypothesized to be the trigger of many types 
of  migraines71. KD feeding effectively treats pain and other symptoms in inflammatory bowel  syndrome72 and 
Parkinson’s  disease73. Overall body pain is alleviated in overweight diabetic  patients74, although it was not speci-
fied if the type of pain was neuropathic. Given the metabolic parallels between KD treatment and fasting, and the 
established efficacy of fasting against rheumatoid  arthritis75,76, a KD could be particularly useful in this disorder. 
Existing studies suggest little clinical  benefit77,78; however, KD treatment in these studies lasted only seven days 
(to parallel a fasting treatment, which was itself effective). We have found that antinociceptive effects of the KD 
evolve over days to  weeks79 and others have found a similar pattern in reduced oxidative  stress18, suggesting that 
longer treatment durations should be attempted in rheumatoid arthritis.
There were several differences between the results with rats and mice. Mice appeared to be more affected 
physiologically by ketogenic diet treatment, with lowered glucose and a trend to lower body mass (not occurring 
in rats) and a more than two-fold higher elevation in β-hydroxybutyrate than in rats. These are clearly species 
related. There were also differences in behavioral outcomes. The ketogenic diet improved tactile allodynia in 
rats at four hour post-injection, but not later, whereas beneficial effects on tactile allodynia in mice appeared in 
the two to four day range and persisted thereafter. Given relative species paw sizes and the currently used doses 
of CFA, the effective dose in mice is substantially higher, and so either or both dose and species could underlie 
these differences in diet responsiveness. Ongoing pain states were unaffected by diet in mice, with a trend to 
improvement in rats. Species differences, however, led us to use different tests for each species. The mouse mar-
ble burying test clearly showed that a state of ongoing pain reduced performance of this behavior. The lack of a 
ketogenic diet effect indicates that either that the diet does not improve spontaneous pain in this model in mice, 
or that marble burying is inappropriate behavior to assess these types of changes.
It is somewhat unclear which of the main metabolic actions of a KD (elevated ketone bodies, lowered and less 
variable glucose) leads to limiting inflammation and inflammatory pain. Certainly, chronically elevated glucose is 
undesirable: high fasting glucose and/or impaired glucose tolerance associate with elevated blood  cytokines80–85, 
C-reactive  protein80–82,86, oxidative  markers87, circulating white blood  cells88, and inflammatory response of white 
blood  cells89. In fact, acute hyperglycemia elevates circulating cytokines through an oxidative  mechanism90. On 
the other hand, elevated ketone bodies themselves seem to have beneficial effects: in vivo and in vitro studies 
show that β-hydroxybutyrate itself moderates the endoplasmic reticulum stress-induced  inflammasome91,92 and 
the NRLP3  inflammasome49,60,92–94 in various organs in a manner apparently unrelated to its use as a substrate 
for the tricarboxylic acid  cycle93. In addition, free fatty acids from a KD might be directly beneficial by reducing 
mitochondrial production of reactive oxygen  species27. Besides being anti-inflammatory, there are other pos-
sible mechanisms for a KD to limit  pain95. Regardless of mechanism, this study and a growing body of evidence 
suggest that pain be added as a variable in more clinical studies of the KD generally, and specifically that more 
studies of KD treatment in clinical inflammatory pain syndromes is warranted.
Table 1.  Effect of diet treatment on physiological parameters. Physiological measures were taken after the end 
of behavioral testing. Control v. ketogenic ***p < 0.001, **p < 0.01, (*)p = 0.06. Rat: n = 12 CD, 14 KD; mouse: 
n = 6 CD, 8 KD.
Species Diet β-hydroxybutyrate (mM) Glucose (mg/dL) Body mass (g)
Rat
Control 0.25 ± 0.06 129.4 ± 4.3 415 ± 58
Ketogenic 1.14 ± 0.14*** 133.6 ± 9.7 418 ± 50
Mouse
Control 0.42 ± 0.05 170.5 ± 9.2 24.1 ± 0.5
Ketogenic 2.78 ± 0.30*** 99.2 ± 11.0** 20.2 ± 1.6(*)
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